O	0	8	Enhanced	Enhance	VBN	B-NP
O	9	19	expression	expression	NN	I-NP
O	20	22	of	of	IN	B-PP
O	23	31	vascular	vascular	JJ	B-NP
O	32	43	endothelial	endothelial	JJ	I-NP
O	44	50	growth	growth	NN	I-NP
O	51	57	factor	factor	NN	I-NP
O	58	60	by	by	IN	B-PP
B-Organism_subdivision	61	72	periodontal	periodontal	JJ	B-NP
O	73	82	pathogens	pathogen	NNS	I-NP
O	83	85	in	in	IN	B-PP
B-Cell	86	94	gingival	gingival	JJ	B-NP
I-Cell	95	106	fibroblasts	fibroblast	NNS	I-NP
O	106	107	.	.	.	O

O	108	116	Vascular	Vascular	JJ	B-NP
O	117	128	endothelial	endothelial	JJ	I-NP
O	129	135	growth	growth	NN	I-NP
O	136	142	factor	factor	NN	I-NP
O	143	144	(	(	(	O
O	144	148	VEGF	VEGF	NN	B-NP
O	148	149	)	)	)	O
O	150	153	has	have	VBZ	B-VP
O	154	162	recently	recently	RB	I-VP
O	163	172	attracted	attract	VBN	I-VP
O	173	182	attention	attention	NN	B-NP
O	183	185	as	as	IN	B-PP
O	186	187	a	a	DT	B-NP
O	188	194	potent	potent	JJ	I-NP
O	195	202	inducer	inducer	NN	I-NP
O	203	205	of	of	IN	B-PP
B-Multi-tissue_structure	206	214	vascular	vascular	JJ	B-NP
O	215	227	permeability	permeability	NN	I-NP
O	228	231	and	and	CC	I-NP
O	232	244	angiogenesis	angiogenesis	NN	I-NP
O	244	245	.	.	.	O

O	246	254	Aberrant	Aberrant	JJ	B-NP
O	255	267	angiogenesis	angiogenesis	NN	I-NP
O	268	270	is	be	VBZ	B-VP
O	271	276	often	often	RB	I-VP
O	277	287	associated	associate	VBN	I-VP
O	288	292	with	with	IN	B-PP
B-Pathological_formation	293	299	lesion	lesion	NN	B-NP
O	300	309	formation	formation	NN	I-NP
O	310	312	in	in	IN	B-PP
O	313	320	chronic	chronic	JJ	B-NP
O	321	334	periodontitis	periodontitis	NN	I-NP
O	334	335	.	.	.	O

O	336	339	The	The	DT	B-NP
O	340	343	aim	aim	NN	I-NP
O	344	346	of	of	IN	B-PP
O	347	350	the	the	DT	B-NP
O	351	358	present	present	JJ	I-NP
O	359	364	study	study	NN	I-NP
O	365	368	was	be	VBD	B-VP
O	369	371	to	to	TO	B-VP
O	372	383	investigate	investigate	VB	I-VP
O	384	387	the	the	DT	B-NP
O	388	398	properties	property	NNS	I-NP
O	399	401	of	of	IN	B-PP
O	402	406	VEGF	VEGF	NN	B-NP
O	407	417	expression	expression	NN	I-NP
O	418	420	in	in	IN	B-PP
O	421	426	human	human	JJ	B-NP
B-Cell	427	435	gingival	gingival	JJ	I-NP
I-Cell	436	447	fibroblasts	fibroblast	NNS	I-NP
O	448	449	(	(	(	O
B-Cell	449	452	HGF	HGF	NN	B-NP
O	452	453	)	)	)	O
O	454	461	culture	culture	NN	B-NP
O	461	462	.	.	.	O

B-Cell	463	466	HGF	HGF	NN	B-NP
O	467	471	were	be	VBD	B-VP
O	472	482	stimulated	stimulate	VBN	I-VP
O	483	487	with	with	IN	B-PP
O	488	506	lipopolysaccharide	lipopolysaccharide	NN	B-NP
O	507	508	(	(	(	O
O	508	511	LPS	LPS	NN	B-NP
O	511	512	)	)	)	O
O	512	513	,	,	,	O
B-Cellular_component	514	521	vesicle	vesicle	NN	B-NP
O	522	523	(	(	(	O
B-Cellular_component	523	525	Ve	Ve	NN	B-NP
O	525	526	)	)	)	O
O	527	530	and	and	CC	O
O	531	536	outer	outer	JJ	B-NP
O	537	545	membrane	membrane	NN	I-NP
O	546	553	protein	protein	NN	I-NP
O	554	555	(	(	(	O
O	555	558	OMP	OMP	NN	B-NP
O	558	559	)	)	)	O
O	560	564	from	from	IN	B-PP
O	565	579	Actinobacillus	Actinobacillus	NN	B-NP
O	580	601	actinomycetemcomitans	actinomycetemcomitan	NNS	I-NP
O	602	605	and	and	CC	O
O	606	619	Porphyromonas	Porphyromonas	NN	B-NP
O	620	630	gingivalis	gingivalis	NN	I-NP
O	630	631	.	.	.	O

B-Cell	632	635	HGF	HGF	NN	B-NP
O	636	650	constitutively	constitutively	RB	B-ADVP
O	651	659	produced	produce	VBD	B-VP
O	660	664	VEGF	VEGF	NN	B-NP
O	665	668	and	and	CC	I-NP
O	669	675	levels	level	NNS	I-NP
O	676	680	were	be	VBD	B-VP
O	681	694	significantly	significantly	RB	I-VP
O	695	703	enhanced	enhance	VBN	I-VP
O	704	705	(	(	(	O
O	705	706	P	P	NN	B-NP
O	708	712	less	less	JJR	B-NP
O	713	717	than	than	IN	I-NP
O	719	720	0	0	CD	I-NP
O	720	721	.	.	.	I-NP
O	721	723	01	01	CD	I-NP
O	723	724	)	)	)	O
O	725	727	by	by	IN	B-PP
O	728	739	stimulation	stimulation	NN	B-NP
O	740	744	with	with	IN	B-PP
B-Cellular_component	745	747	Ve	Ve	NN	B-NP
O	748	751	and	and	CC	I-NP
O	752	755	OMP	OMP	NN	I-NP
O	756	760	from	from	IN	B-PP
O	761	762	A	A	NN	B-NP
O	762	763	.	.	.	O
O	764	785	actinomycetemcomitans	actinomycetemcomitan	NNS	B-NP
O	786	789	and	and	CC	I-NP
O	790	791	P	P	NN	I-NP
O	791	792	.	.	.	I-NP
O	793	803	gingivalis	gingivalis	NN	I-NP
O	804	806	at	at	IN	B-PP
O	807	821	concentrations	concentration	NNS	B-NP
O	822	824	of	of	IN	B-PP
O	825	827	10	10	CD	B-NP
O	828	834	microg	microg	NN	I-NP
O	834	835	/	/	SYM	B-NP
O	835	837	ml	ml	NN	I-NP
O	838	840	or	or	CC	O
O	841	847	higher	high	JJR	B-ADVP
O	847	848	.	.	.	O

O	849	851	On	On	IN	B-PP
O	852	855	the	the	DT	B-NP
O	856	861	other	other	JJ	I-NP
O	862	866	hand	hand	NN	I-NP
O	866	867	,	,	,	O
O	868	872	VEGF	VEGF	NN	B-NP
O	873	879	levels	level	NNS	I-NP
O	880	884	were	be	VBD	B-VP
O	885	888	not	not	RB	I-VP
O	889	898	increased	increase	VBN	I-VP
O	899	901	by	by	IN	B-PP
O	902	905	LPS	LPS	NN	B-NP
O	906	917	stimulation	stimulation	NN	I-NP
O	917	918	.	.	.	O

O	919	923	VEGF	VEGF	NN	B-NP
O	924	928	mRNA	mRNA	NN	I-NP
O	929	939	expression	expression	NN	I-NP
O	940	943	was	be	VBD	B-VP
O	944	948	also	also	RB	I-VP
O	949	957	observed	observe	VBN	I-VP
O	958	960	in	in	IN	B-PP
B-Cellular_component	961	963	Ve	Ve	NN	B-NP
O	963	964	-	-	HYPH	B-NP
O	965	968	and	and	CC	I-NP
O	969	972	OMP	OMP	NN	I-NP
O	972	973	-	-	HYPH	O
O	973	983	stimulated	stimulate	VBN	B-NP
B-Cell	984	987	HGF	HGF	NN	I-NP
O	987	988	.	.	.	O

O	989	990	A	A	DT	B-NP
B-Multi-tissue_structure	991	999	vascular	vascular	JJ	I-NP
O	1000	1012	permeability	permeability	NN	I-NP
O	1013	1024	enhancement	enhancement	NN	I-NP
O	1025	1026	(	(	(	O
O	1026	1029	VPE	VPE	NN	B-NP
O	1029	1030	)	)	)	O
O	1031	1036	assay	assay	NN	B-NP
O	1037	1040	was	be	VBD	B-VP
O	1041	1050	performed	perform	VBN	I-VP
O	1051	1056	using	use	VBG	B-VP
O	1057	1063	guinea	guinea	NN	B-NP
O	1064	1068	pigs	pig	NNS	I-NP
O	1069	1071	to	to	TO	B-VP
O	1072	1081	ascertain	ascertain	VB	I-VP
O	1082	1089	whether	whether	IN	B-SBAR
B-Organism_substance	1090	1101	supernatant	supernatant	NN	B-NP
O	1102	1106	from	from	IN	B-PP
B-Cell	1107	1115	cultures	culture	NNS	B-NP
O	1116	1118	of	of	IN	B-PP
B-Cellular_component	1119	1121	Ve	Ve	NN	B-NP
O	1121	1122	-	-	HYPH	B-NP
O	1123	1126	and	and	CC	I-NP
O	1127	1130	OMP	OMP	NN	I-NP
O	1130	1131	-	-	HYPH	I-NP
O	1131	1141	stimulated	stimulate	VBN	I-NP
B-Cell	1142	1145	HGF	HGF	NN	I-NP
O	1146	1153	enhance	enhance	VBP	B-VP
B-Multi-tissue_structure	1154	1162	vascular	vascular	JJ	B-NP
O	1163	1175	permeability	permeability	NN	I-NP
O	1176	1178	in	in	FW	B-ADVP
O	1179	1183	vivo	vivo	FW	I-ADVP
O	1183	1184	.	.	.	O

B-Organism_substance	1185	1196	Supernatant	Supernatant	JJ	B-ADJP
O	1197	1201	from	from	IN	B-PP
B-Cell	1202	1210	cultures	culture	NNS	B-NP
O	1211	1213	of	of	IN	B-PP
B-Cellular_component	1214	1216	Ve	Ve	NN	B-NP
O	1216	1217	-	-	HYPH	B-NP
O	1218	1221	and	and	CC	I-NP
O	1222	1225	OMP	OMP	NN	I-NP
O	1225	1226	-	-	HYPH	O
O	1226	1236	stimulated	stimulate	VBN	B-NP
B-Cell	1237	1240	HGF	HGF	NN	I-NP
O	1241	1249	strongly	strongly	RB	B-ADVP
O	1250	1257	induced	induce	VBD	B-VP
O	1258	1261	VPE	VPE	NN	B-NP
O	1261	1262	.	.	.	O

O	1263	1267	This	This	DT	B-NP
O	1268	1271	was	be	VBD	B-VP
O	1272	1280	markedly	markedly	RB	I-VP
O	1281	1291	suppressed	suppress	VBN	I-VP
O	1292	1296	upon	upon	IN	B-PP
O	1297	1309	simultaneous	simultaneous	JJ	B-NP
O	1310	1319	injection	injection	NN	I-NP
O	1320	1322	of	of	IN	B-PP
O	1323	1327	anti	anti	AFX	B-NP
O	1327	1328	-	-	HYPH	I-NP
O	1328	1332	VEGF	VEGF	NN	I-NP
O	1333	1343	polyclonal	polyclonal	JJ	I-NP
O	1344	1354	antibodies	antibody	NNS	I-NP
O	1355	1359	with	with	IN	B-PP
O	1360	1363	the	the	DT	B-NP
B-Organism_substance	1364	1375	supernatant	supernatant	NN	I-NP
O	1375	1376	.	.	.	O

O	1377	1384	Heating	Heating	NN	B-NP
O	1385	1388	and	and	CC	I-NP
O	1389	1397	protease	protease	NN	I-NP
O	1398	1407	treatment	treatment	NN	I-NP
O	1408	1410	of	of	IN	B-PP
O	1411	1414	the	the	DT	B-NP
O	1415	1425	stimulants	stimulant	NNS	I-NP
O	1426	1433	reduced	reduce	VBD	B-VP
O	1434	1437	the	the	DT	B-NP
O	1438	1442	VEGF	VEGF	NN	I-NP
O	1443	1452	enhancing	enhance	VBG	B-VP
O	1453	1459	levels	level	NNS	B-NP
O	1460	1462	in	in	IN	B-PP
B-Cellular_component	1463	1465	Ve	Ve	NN	B-NP
O	1466	1469	and	and	CC	O
O	1470	1473	OMP	OMP	NN	B-NP
O	1474	1476	in	in	FW	B-ADVP
O	1477	1482	vitro	vitro	FW	I-ADVP
O	1482	1483	.	.	.	O

O	1484	1489	These	These	DT	B-NP
O	1490	1497	results	result	NNS	I-NP
O	1498	1505	suggest	suggest	VBP	B-VP
O	1506	1510	that	that	IN	B-SBAR
B-Cellular_component	1511	1513	Ve	Ve	NN	B-NP
O	1514	1517	and	and	CC	I-NP
O	1518	1521	OMP	OMP	NN	I-NP
O	1522	1525	may	may	MD	B-VP
O	1526	1528	be	be	VB	I-VP
O	1529	1536	crucial	crucial	JJ	B-NP
O	1537	1541	heat	heat	NN	I-NP
O	1541	1542	-	-	HYPH	B-NP
O	1542	1548	labile	labile	JJ	I-NP
O	1549	1552	and	and	CC	I-NP
O	1553	1561	protease	protease	NN	I-NP
O	1561	1562	-	-	HYPH	B-NP
O	1562	1571	sensitive	sensitive	JJ	I-NP
O	1572	1582	components	component	NNS	I-NP
O	1583	1585	of	of	IN	B-PP
B-Organism_subdivision	1586	1597	periodontal	periodontal	JJ	B-NP
O	1598	1607	pathogens	pathogen	NNS	I-NP
O	1608	1612	that	that	WDT	B-NP
O	1613	1620	enhance	enhance	VBP	B-VP
O	1621	1625	VEGF	VEGF	NN	B-NP
O	1626	1636	expression	expression	NN	I-NP
O	1636	1637	.	.	.	O

O	1638	1640	In	In	IN	B-PP
O	1641	1649	addition	addition	NN	B-NP
O	1649	1650	,	,	,	O
O	1651	1655	VEGF	VEGF	NN	B-NP
O	1656	1661	might	might	MD	B-VP
O	1662	1664	be	be	VB	I-VP
O	1665	1675	associated	associate	VBN	I-VP
O	1676	1680	with	with	IN	B-PP
O	1681	1684	the	the	DT	B-NP
O	1685	1693	etiology	etiology	NN	I-NP
O	1694	1696	of	of	IN	B-PP
O	1697	1710	periodontitis	periodontitis	NN	B-NP
O	1711	1713	in	in	IN	B-PP
O	1714	1717	its	its	PRP$	B-NP
O	1718	1723	early	early	JJ	I-NP
O	1724	1730	stages	stage	NNS	I-NP
O	1731	1740	according	accord	VBG	B-PP
O	1741	1743	to	to	TO	B-PP
O	1744	1762	neovascularization	neovascularization	NN	B-NP
O	1763	1773	stimulated	stimulate	VBN	B-VP
O	1774	1776	by	by	IN	B-PP
B-Organism_subdivision	1777	1788	periodontal	periodontal	JJ	B-NP
O	1789	1798	pathogens	pathogen	NNS	I-NP
O	1799	1806	causing	cause	VBG	B-VP
O	1807	1815	swelling	swelling	NN	B-NP
O	1816	1819	and	and	CC	I-NP
B-Pathological_formation	1820	1825	edema	edema	NN	I-NP
O	1825	1826	.	.	.	O

